Sign in Subscribe
Stock exchanges

Securities Fraud Investigation into Hims & Hers Health Inc.

Strategic Insights

— 1 min read

Investors who purchased Hims & Hers Health Inc. ("Hims & Hers") stock between April 29, 2025, and June 22, 2025, may be eligible to participate in a class action lawsuit as lead plaintiffs. The suit alleges that the company failed to disclose risks tied to its compounded drug offerings, leading to a significant drop in stock price following Novo Nordisk's termination of their collaboration. Hims & Hers is under investigation by the Securities Exchange Act of 1934 for potential violations of securities regulations.

Key Takeaways:

  • The investigation into Hims & Hers Health Inc. concerns potential violations of the Securities Exchange Act of 1934, specifically regarding the company's regulatory compliance and business operations.
  • The company's stock dropped over 34% after Novo Nordisk terminated their collaboration on June 23, 2025.
  • A class action lawsuit has been filed alleging that Hims & Hers failed to disclose risks tied to its compounded drug offerings.
  • The class period for affected investors spans from April 29, 2025, through June 22, 2025.
  • Lead plaintiff status in the case is open to investors who acquired Hims & Hers stock within the designated class period.
  • Berger Montague, a law firm with experience in securities litigation, is representing the lead plaintiff and other harmed investors.
  • Hims & Hers is a pharmaceutical company with a presence on the New York Stock Exchange (NYSE) under the ticker symbol HIMS.

Statistics:

  • Hims & Hers stock dropped over 34% after Novo Nordisk terminated their collaboration on June 23, 2025.
  • The class period for affected investors spans from April 29, 2025, through June 22, 2025.
  • Berger Montague has represented individual and institutional investors for over five decades, serving as lead counsel in courts throughout the United States.

Sources:

  • Berger Montague press release announcing a securities fraud investigation into Hims & Hers Health Inc.
  • Class action lawsuit filed against Hims & Hers Health Inc. alleging failure to disclose risks tied to its compounded drug offerings.

Read more